Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AC 170 0.24% | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AC 170 0.24% | Drug | 1 drop in each eye 2 times daily for 1 week |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmax values of AC 170 0.24% | Plasma samples will be drawn at specified time points and then analyzed to determine Cmax values of AC 170 0.24% in the plasma | 1 week |
| Tmax values of AC 170 0.24% | Plasma samples will be drawn at specified time points and then analyzed to determine Tmax values of AC 170 0.24% in the plasma | 1 week |
| AUC values of AC 170 0324% | Plasma samples will be drawn at specified time points and then analyzed to determine AUC values of AC 170 0.24% in the plasma | 1 week |
| T 1/2 values of AC 170 0.24% | Plasma samples will be drawn at specified time points and then analyzed to determine T 1/2 values of AC 170 0.24% in the plasma | 1 week |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Andover Eye Associates | Andover | Massachusetts | 01810 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided